Patent · US Active

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

US9822181B2 · kind B2 · utility

57Cited by

59References

32Claims

0Family size

Assignee

Macrogenics, Inc. · US

Inventors

Ezio Bonvini · Potomac, US
Leslie S. Johnson · Travilah, US
Ling Huang · Bethesda, US
Paul A. Moore · North Potomac, US
Gurunadh Reddy Chichili · Germantown, US
Ralph Alderson · Gaithersburg, US

Key dates

Filing date	Aug 20, 2014
Grant date	Nov 21, 2017
Priority date	—
Expiry date	Aug 20, 2034

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to sequence-optimized CD 123×CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.